Scarica l'app Stockscreener
20.73
3.98%
-0.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Baillie Gifford & Co. Sells 1,031,956 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Tuesday - MarketBeat
Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight - GlobeNewswire Inc.
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
(DNLI) On The My Stocks Page - Stock Traders Daily
Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9%What's Next? - MarketBeat
abrdn plc Has $8.20 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Deutsche Bank Initiates Coverage of Denali Therapeutics (MUN:4DN) with Buy Recommendation - Nasdaq
Deutsche Bank Initiates Coverage of Denali Therapeutics (DNLI) with Buy Recommendation - Nasdaq
Deutsche Bank sets $31 target for Denali Therapeutics stock By Investing.com - Investing.com Australia
Stifel maintains Buy on Denali Therapeutics, $37 target - MSN
Stifel maintains Buy on Denali Therapeutics, $37 target By Investing.com - Investing.com Australia
Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $38.00 - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2%What's Next? - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Up 5.1% in January - MarketBeat
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Denali Therapeutics Announces Primary Analysis and - GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - Marketscreener.com
Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa - Marketscreener.com
Where are the Opportunities in (DNLI) - Stock Traders Daily
Leerink Partnrs Has Negative Outlook of DNLI FY2025 Earnings - MarketBeat
Zacks Research Has Bearish Estimate for DNLI FY2024 Earnings - MarketBeat
Denali Gains 26.6% in a Year: How Should You Play the Stock? - MSN
Denali Therapeutics Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - Simply Wall St
What is Leerink Partnrs’ Forecast for DNLI FY2025 Earnings? - Defense World
Zacks Research Has Negative Outlook of DNLI FY2024 Earnings - Defense World
The Goldman Sachs Group Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00 - MarketBeat
Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire
Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - StockTitan
The Goldman Sachs Group Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%Time to Sell? - MarketBeat
How To Trade (DNLI) - Stock Traders Daily
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):